Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal

Deal Worth Up To $2.37bn

 
• By Andrew McConaghie
Biogen_Switzerland
Biogen's filing of aducanumab is the most anticipated biopharma sector event in 2020

More from Business

More from Scrip